Hypoactive Sexual Desire Disorder (HSDD) is an undertreated condition characterized by low libido that causes distress and difficulty in interpersonal relationships. With a new FDA-approved treatment method, we feel confident in treating this condition and offering a solution for women who experience HSDD.
Vyleesi™ is the first as-needed treatment for women who experience HSDD and has been rated “excellent” or “very good” by most surveyed patients. Women have reported high ratings for its ease of use and convenience. Vyleesi™ increases sexual desire and can be taken when you choose, putting you in control of your sexual behavior.
The small, compact treatment is self-injectable and only takes five seconds but will last 12 to 24 hours. Women are able to receive four insurance-covered treatments each month but can take up to eight treatments. Effects should resolve within 12 hours but patients should not take more than one dose every 24 hours.
How Does Vyleesi™ Work?
Women with HSDD have an imbalance of neurotransmitter activity in their brains. Other disorders affect the excitatory signals such as dopamine, norepinephrine or oxytocin levels but HSDD specifically affects melanocortin (MC). Vyleesi™ targets MCs in the brain, and aids activation of several receptors that produce MCs. The increase in excitatory signals will transiently increase blood pressure while reducing heart rate to increase sexual desire.
The most common side effect reported by women was nausea. However, for most patients nausea only lasted about two hours after the first dose. By the second dose, only about three percent of patients were still experiencing nausea. Other side effects can include flushing, injection site reactions, headaches, and vomiting. The majority of events were reported to be mild to moderate in intensity.
If you have HSDD or have any questions about this disorder, Vyleesi™ could be the answer. Talk to your doctor about treatment options to see if Vyleesi™ could benefit you.